Study of an oral medication in patients with moderate to severe atopic dermatitis

What we are studying

Study of the efficacy and safety of oral medication (baricitinib) versus placebo in patients with moderate to severe atopic dermatitis (eczema) who have not had good response with topical treatments within 6 months of screening visit.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
  • Not Hispanic or Latino
  • Ages 18+

Eligibility Criteria

  • Atopic Dermatitis (Eczema) Moderate to Severe

What is involved

  • TB Testing/Chest X-ray Lab Work ECG's

Compensation

$50.00 per completed visit.

Contact Information

Study Coordinator
dermadvertising
Email
dermadvertising@wakehealth.edu
Phone
336-716-3775
Principal Investigator
Lindsay Strowd, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.